UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000005058
Receipt number R000006014
Scientific Title Phase II study of S-1 chemotherapy in elderly patients with advanced non-small cell lung cancer harboring no EGFR gene mutation
Date of disclosure of the study information 2011/02/14
Last modified on 2011/05/17 13:22:53

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase II study of S-1 chemotherapy in elderly patients with advanced non-small cell lung cancer harboring no EGFR gene mutation

Acronym

Phase II study of S-1 chemotherapy in elderly patients with advanced non-small cell lung cancer harboring no EGFR gene mutation (ALCSG 1002)

Scientific Title

Phase II study of S-1 chemotherapy in elderly patients with advanced non-small cell lung cancer harboring no EGFR gene mutation

Scientific Title:Acronym

Phase II study of S-1 chemotherapy in elderly patients with advanced non-small cell lung cancer harboring no EGFR gene mutation (ALCSG 1002)

Region

Japan


Condition

Condition

Non-small cell lung cancer

Classification by specialty

Pneumology

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

The present study evaluates the efficacy and safety of single-agent S-1 in elderly patients with advanced NSCLC harboring no EGFR gene mutation.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Response rate.

Key secondary outcomes

Disease control rate, overall survival, progression free survival, safety.


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

single agent S-1

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

70 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Eligibility includes; 1) patients having a histological or cytological diagnosis of NSCLC, 2) NSCLC at clinical stage IIIA to IV, 3) patients aged 70 and over 70 years, 4) an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, 5) patients having adequate organ function, 6) no prior chemotherapy for NSCLC, 7) NSCLC harboring no EGFR gene mutation, 8) life expectancy of longer than 3 months.

Key exclusion criteria

Patients are excluded if they have; 1) severe concomitant diseases, 2) interstitial pneumonia, 3) NSCLC with EGFR gene mutations, 4) no measurable lesion.

Target sample size

30


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yoshinobu Ohsaki

Organization

Asahikawa Medical University Hospital

Division name

Respiratory Center

Zip code


Address

2-1-1-1 Midorigaoka-higashi, Asahikawa-shi, Hokkaido, 078-8510 Japan

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name

Organization

Asahikawa Medical University Hospital

Division name

Respiratory Center

Zip code


Address


TEL


Homepage URL


Email

okumura-@asahikawa-med.ac.jp


Sponsor or person

Institute

Respiratory Center, Asahikawa Medical University Hospital

Institute

Department

Personal name



Funding Source

Organization

Respiratory Center, Asahikawa Medical University Hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor

Asahikawa Lung Cancer Study Group (ALCSG)

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

旭川医科大学病院(北海道)、旭川医療センター(北海道)


Other administrative information

Date of disclosure of the study information

2011 Year 02 Month 14 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2011 Year 01 Month 28 Day

Date of IRB


Anticipated trial start date

2011 Year 02 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2011 Year 02 Month 09 Day

Last modified on

2011 Year 05 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006014


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name